Drug Profile
AP 1531
Alternative Names: BGC-20-1531; PGN-1531Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Asterand plc
- Developer BTG
- Class Antimigraines
- Mechanism of Action Prostaglandin E4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 23 Feb 2016 Discontinued - Phase-I for Migraine in United Kingdom (PO)
- 12 Jan 2016 BTG withdraw a phase II trial in Migraine in Denmark, Norway and United Kingdom (NCT00888680)